A dangerous drug-resistant superbug is surging in European hospitals, spreading between patients and becoming increasingly harder to treat, the EU’s disease agency warns.
Cases of bloodstream infections caused by treatment-resistant Klebsiella pneumoniae have increased by 72% between 2019 and 2025 — far from the target of cutting rates by 5% by 2030 — according to the latest bundle of reports from the European Centre for Disease Prevention and Control, out Wednesday.
Infections linked to this bacterium, which have been climbing steadily for the past few years, are a significant threat to patients in hospitals and have a high mortality rate typically between 40% and 70%. Analyses show that several of its strains are becoming resistant to nearly all antibiotics — including new ones — and can cause severe illness and death.
The findings on treatment-resistant Klebsiella pneumoniae were “the biggest concern” among all the data collected on superbugs in Europe over the past year, Christian Giske, who leads this work at ECDC, told a press briefing.
It’s one example of the dangers posed by antimicrobial resistance — the ability of bacteria and fungi to evolve to be resistant to drugs designed to destroy them — which is estimated to kill 35,000 people in the EU, Iceland and Norway every year. For Europe, this is a “major public health threat,” Giske said.
Despite progress in some areas, the latest reports show the EU is still far from reaching its 2030 targets to reduce rates of drug-resistant infections. Among the challenges is the limited number of new drugs available to treat such infections.
The news comes as Europe’s new pharmaceutical legislation is set to be signed into law in December and includes measures to boost the discovery and development of new antibiotics — through a market monopoly perk for industry and a push for steady payment models for countries to buy them.
Harder to tackle
Given that it spreads between patients, tackling the surging rates of Klebsiella requires stronger infection prevention and control measures in hospitals, the ECDC warns. This includes strengthening hand hygiene, ensuring correct use of personal protective equipment like gloves, and effective environmental cleaning and disinfection.
And while similar measures have helped to significantly cut EU rates of the better-known hospital-acquired superbug, MRSA, for Klebsiella, missing even the tiniest surface can lead to the bacteria spreading.
“Klebsiella is a gut bacterium, and it may have more powerful reservoirs in the body,” Giske told reporters during the press briefing. “What works for MRSA might not be sufficient for Klebsiella. The adherence to good [infection prevention and control] needs to be even higher to contain a problem like Klebsiella.”
Countries have successfully fought back against infections with MRSA — otherwise known as drug-resistant Staphylococcus aureus: In 2025, bloodstream infections caused by this bacterium were 19% lower than in 2019, surpassing the target of reducing them by 15% by 2030.
While countries have been successfully using infection control measures to drive down rates of MRSA, Klebsiella is harder to tackle, said Giske.
E. coli drug-resistant infections are also proving difficult to drive down: Despite a target to reduce these infections by 10% by 2030, the EU saw a 16.4% increase between 2019 and 2025.
Mixed progress
It’s also key to ensure reduced and targeted use of antibiotics, as avoiding antibiotics when they are not needed can reduce the risk of bacteria becoming resistant to them.
New estimates show that antibiotic consumption in the EU dropped by 5% between 2019 and 2025, well below the 20% target by 2030.
Meanwhile, the EU is slowly making progress in using the right types of antibiotics. It’s inching closer to its goal of ensuring that at least 65% of antibiotics being used in Europe are the correct drugs — as determined by the World Health Organization — with the proportion reaching 62.5% in 2025.
“We are still behind with several of the EU’s 2030 targets to counter antimicrobial resistance,” ECDC Director Pamela Rendi-Wagner said in a statement.
Genomic surveillance is one recent innovation making a difference. This helps authorities to assess more quickly how these resistant bacteria are spreading, Rendi-Wagner said.
“This in turn means we can act sooner to stop transmission, more effectively guide treatment decisions, and identify where new antibiotics are most urgently needed,” she added.
European hospitals must urgently tighten infection control and accelerate access to effective drugs. At the same time, pragmatic cooperation on public-health issues — including sharing expertise and resources across political divides — would strengthen Europe’s ability to respond. There is no benefit to politicising a threat that can spread everywhere; practical partnerships, even with countries often painted as rivals, could help save lives.